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Abstract 
 
Membranoproliferative glomerulonephritis (MPGN) is an immune-mediated disease that is 
characterised by mesangial hypercellularity and endocapilliary proliferation with capillary 
wall remodeling which results in thickening of the glomerular basement membrane. (1)  
MPGN was traditionally classified on electron microscopy findings into MPGN type I, II, 
and III. Multiple genetic risk factors have been identified for MPGN II now referred to as 
dense deposit disease; however, relatively little is known regarding genetic risk factors for 
MPGN type I and III.  
 A reclassification scheme that better reflects the pathophysiology of MPGN has been 
implemented. This scheme divides MPGN into immune-complex-mediated and 
complement-mediated MPGN. Previous descriptions of familial MPGN suggest that this 
entity falls within the category of complement-mediated MPGN.  
 
We describe a South African family with four family members affected with immune-
complex-mediated MPGN. All other asymptomatic contactable family members were 
tested for proteinuria and haematuria and a pedigree for the family was established with an 
autosomal recessive with incomplete penetrance inheritance pattern or a multigenic 
inheritance pattern. 
 
A systematic review was then performed using the search terms of "inherited MPGN" and 
"Familial MPGN". In the systematic review of familial MPGN from 1981-2014, nine 
reports containing twelve families were reviewed totaling thirteen families including the 
South African family. Six families were found to have immune-complex-mediated MPGN 
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and five families had complement-mediated MPGN. The data of two families was limited 
and thus couldn’t be reclassified.  
 
Most of the family members presented with nephrotic syndrome; and more family 
members in the complement-mediated MPGN group (41%) had a decreased serum 
complement versus 14% in the immune-complex-mediated group. The mean age of 
diagnosis, of the family members in the immune-complex-mediated group was 15 years of 
age with a mean age at end stage renal disease of 20 years of age. The mean age of 
diagnosis in the complement-mediated group was also 15 years of age with a mean age at 
end stage renal disease of 25 years of age. Inheritance patterns varied greatly between the 
studies with no clear inheritance pattern being established. 
 
In a previous family studied, a link was found between chromosome 1q, a locus containing 
genes for factors affecting the complement cascade. (4) However the systematic review 
shows that this family falls under the reclassification of complement-mediated MPGN. 
Thus it is unknown if chromosome 1q is also involved in the pathogenesis of inherited 
immune-complex-mediated MPGN. 
 
By describing this South African family with familial MPGN and the systematic review of 
familial MPGN case studies, we demonstrate that familial MPGN occurs through immune-
complex-mediated and complement-mediated pathways. Based on our findings, the current 
classification of MPGN should be modified to include familial immune-complex-mediated 
MPGN as a fourth category under immune-complex-mediated MPGN. Further studies are 
required to assess the inheritance patterns as well as the underlying genetic abnormality 
related to immune-complex-mediated MPGN. 
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INTRODUCTION 
 
 
Membranoproliferative glomerulonephritis (MPGN) is an immune mediated 
glomerulonephritis that is characterised histopathologically by mesangial hypercellularity, 
endocapilliary proliferation with capillary wall remodelling which results in thickening of 
the glomerular basement membrane. (1) It is often a chronic, progressive renal disease with 
a variable clinical presentation, usually that of an acute nephrotic or nephritic syndrome. 
(2) While MPGN was traditionally classified on electro-microscopy findings into MPGN 
type I, MPGN type II and MPGN type III, (1) the term MPGN type II was discarded for 
the inclusive name of dense deposit disease (DDD). (3) Multiple genetic risk factors have 
been identified for DDD (3), while relatively little is known about the underlying genetic 
risk factors for MPGN type I and type III, hence this study will focus on familial MPGN 
type I and III. 
 
There is a familial incidence of 2.6- 4% of MPGN type I and type III (5) with multiple 
patterns of inheritance being considered, the commonest being that of an autosomal 
dominant or x-linked pattern of inheritance. (6,7) A familial form of MPGN type III has 
been identified with an autosomal dominant pattern of inheritance and it is genetically 
linked to band 1q31-32. (4) It has also been suggested that the gene and its function, 
predisposing to MPGN, may be modified by other genes that control the immune response, 
and hence the difference in the modes of disease expression. (7)  
 
With recent advances in the understanding of the pathophysiology underlying the 
formation of MPGN, a reclassification scheme has been recommended to divide MPGN 
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into immune-complex-mediated MPGN and complement mediated MPGN. With this 
change in definition the previous descriptions of familial MPGN should also change, 
however due to the limited number of reported cases of familial MPGN, little is known 
about the epidemiology as well as the progression of disease. By describing the clinical 
and pathological features of a South African family with familial MPGN type I, as well as 
reviewing reported cases of familial MPGN between 1981 and 2014, an attempt was made 
at classifying familial MPGN within the new definitions, as well as reviewing the 
epidemiology and disease progression and lastly, further evidence is provided for the 
genetic basis underlying this genetic disease. 
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LITERATURE REVIEW 
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Idiopathic membranoproliferative glomerulonephritis (MPGN) is an immune mediated 
glomerulonephritis that is chronic and often progressive. It is characterised 
histopathologically by mesangial cell hypercellularity and endocapilliary proliferation with 
capillary wall remodelling which results in thickening of the glomerular basement 
membrane. MPGN commonly presents in childhood and the clinical presentation and 
disease course is variable, mainly due to differences in the pathogenesis of the disease. (1) 
 
Traditionally MPGN was classified on electron-microscopy findings into three types 
MPGN type I; MPGN type II; MPGN type III. (1) MPGN type II (DDD) was identified as 
separate distinct disease entity and MPGN type III was considered a variant of MPGN type 
I. (6)  Due to recent advances in the understanding of the pathophysiology underlying the 
pathogenesis of MPGN, a reclassification scheme has been recommended to divide MPGN 
into immune-complex-mediated MPGN and complement-mediated MPGN based on the 
underlying pathophysiology. (1)  
 
The pathophysiology of both immune-complex mediated MPGN and complement 
mediated MPGN revolves around the complement system. The complement cascade can 
be initiated via three pathways, namely the alternative, classical and lectin pathways. (1)  
All three pathways meet at the nodal point of the pathway, namely C3, to create the 
enzyme complex C3 convertase.  
 
This complex then splits C3 into C3a and C3b. C3b under factor B and D combines with 
C3 convertase forming more C3 convertase resulting in an amplification loop. The 
association of C3 convertase with C3b also generates C5 convertase which cleaves C5 into 
C5a and C5b, which activates the terminal complement complex pathway which forms, via 
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C5b-C9, the membrane-attack complex (MAC) on cell surfaces finally resulting in cell 
lysis of the mesangium and capillary walls, known as the injury phase. (1)   
 
The injury phase is accompanied by an inflammatory or proliferative phase with an influx 
of inflammatory cells and the release of proteases and cytokines resulting in proteinuria 
and haematuria. Ultimately loss of fenestration occurs in the endothelial cells and the 
glomerular basement membrane becomes disrupted with effacement of the foot processes 
on podocytes.  
 
During the reparative phase, mesangial expansion occurs due to the formation of new 
mesangial matrix along with the formation of a new basement membrane, which results in 
immune complexes, complement factors, cellular elements, and matrix material being 
trapped within the two basement membranes, resulting in the double contours seen along 
the capillary walls. 
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Figure 1: Normal Glomerular Capillary Wall and Immune-Complex MPGN. 
Panel A is a schematic diagram of the normal glomerular capillary wall and glomerular basement 
membrane. 
 
Panel B is a schematic diagram of Immune-Complex MPGN caused via activation of the classical 
pathway. The injury phase results from the deposition of immune complexes and complement factors 
of the classical and terminal pathways, followed by an influx of leukocytes, leading to a proliferative 
phase, with the release of cytokines and proteases (labeled P) resulting in damage to the capillary 
walls.  Loss of fenestration occurs in the endothelial cells along with disruption of the glomerular 
basement membrane with the effacement of the podocyte foot processers. With repair a new basement 
membrane is formed, trapping immune complexes, complement factors, cellular elements, and matrix 
material within the two basement membranes, resulting in double contours seen along the capillary 
walls  
 
Yellow oval structures indicate complement factors. The term sMAC denotes soluble membrane-
attack complex. 
 
Reproduced with permission from Sethi S, Fervenza FC. N Engl J Med 2012;366:1119-1131, 
Copyright Massachusetts Medical Society. 
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Thus the pathological feature found on light microscopy (LM) is the appearance of tram 
tracks or double contours of the basement membrane, while typically electron microscopy 
(EM) reveals mesangial and subendothelial deposits and occasionally intramembranous 
and subepithelial deposits. EM shows the replacement of the glomerular basement 
membrane by wavy dense osmiophilic, sausage-shaped deposits in MPGN type II (DDD). 
This is the only time that EM can distinguish that the MPGN is complement mediated, 
otherwise immunofluorescence findings are used to distinguish between complement-
mediated MPGN and immune-complex-mediated MPGN. Figure 2 contains images of LM, 
IFM and EM features of MPGN. 
 
The injury phase of immune complex mediated MPGN (figure 1) occurs due to the 
deposition of immune complexes into the glomeruli, which activates the classical pathway 
of the complement system, resulting in the formation of the membrane attack complex on 
the mesangium and capillary walls. (1)  The proliferative and reparative phases then 
follow. Thus kidney biopsy specimens show immunoglobulin and complement deposition 
on IFM.  
 
The immune complex deposition in the glomeruli are due to a.) Antigen antibody 
complexes from chronic infections mainly hepatitis C; b.) Increased immune complexes 
secondary to autoimmune disease and c.) Glomerular deposition of monoclonal 
immunoglobulins secondary to monoclonal gammopathies.(1) 
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 Figure 2: MPGN findings on light, immunofluorescence and electron microscopy.  
 
A-E Shows Immune-mediated MPGN 
 
A: Light microscopy shows an MPGN pattern of injury 
B: Immunofluorescence microscopy shows positive staining for IgM 
C: Immunofluorescence microscopy shows positive staining for kappa light chains. 
D: Immunofluorescence microscopy shows negative staining for lambda light chains. 
E: Double-contour formation and subendothelial deposits (arrow) seen on EM. 
 
F- J shows Complement-mediated MPGN 
 
F: MPGN pattern of injury on LM 
G: Bright C3 staining on immunofluorescence microscopy with negative staining for Immunoglobulin, C1q, kappa, and lambda light chains. 
H: Electron microscopy shows dense osmiophilic deposits (arrow) along the glomerular basement membranes in dense-deposit disease. 
 I and J: mesangial (white arrows), subendothelial (black arrows), intramembranous (black arrowhead), and subepithelial deposits (white arrowheads) 
and double contours in C3 glomerulonephritis on EM.  
 
Reproduced with permission from Sethi S, Fervenza FC. N Engl J Med 2012;366:1119-1131,  Copyright Massachusetts Medical Society. 
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Immune-complex-mediated MPGN associated with a monoclonal gammopathy has a 
“monotypic immunoglobulin, usually kappa or lambda light chains restriction,” (1)  while 
MPGN associated with hepatitis C infection demonstrates IgM, IgG, C3 and kappa and 
lambda light chains. (1)  Autoimmune diseases associated with immune-complex-mediated 
MPGN often have many immunoglobulins and complement proteins IgG, IgM, IgA, C1q, 
C3 and kappa and lambda light chains. 
 
The injury phase of complement- mediated MPGN (figure 3) occurs due to dysregulation 
of the alternative complement pathway caused by autoantibodies to complement regulating 
proteins or mutations in those proteins. (1,3,8) In the circulation, the alternative 
complement cascade pathway is constantly active at low levels, thus activation is 
tightly protected to prevent self-harm. Different complement regulating and 
complement-inhibiting proteins work at different sites along the complement cascade 
pathway. These proteins include factors H and I, factor H related proteins 1-5, 
membrane cofactor protein (CD46), decay-accelerating factor (CD55), CD59, 
complement receptor 1 and complement receptor of the immunoglobulin 
superfamily. (1)   
 
Mutations in anyone of the above can result in the dysregulation of the alternative 
pathway. Hence immunoglobulins are not directly involved and on 
immunofluorescence there is absence of immunoglobulins but shows marked 
complement deposition.  Patients typically have hypocomplementaemia, due to the 
hyperactivity of the alternative complement cascade although some are recorded 
with normal levels.(3) 
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Figure 3. Complement-Mediated MPGN. 
 
Above is a schematic diagram of MPGN associated with dysregulation of the alternative pathway.  
 
Mutations and antibodies to complement-regulating proteins result in the deposition of 
complement factors of the alternative pathway and terminal complement complex causing the 
Injury phase. The proliferative and reparative phases are as described for immune-complex–
mediated MPGN in Figure 1.  
 
Antibodies (Y-shaped pink structures) are shown against complement factor H (CFH), factor I 
(CFI), factor B, and C3 convertase (C3 nephritic factor).  
 
Reproduced with permission from Sethi S, Fervenza FC. N Engl J Med 2012;366:1119-1131, 
Copyright Massachusetts Medical Society. 
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From this new definition, familial MPGN Type II or DDD is now classified under 
complement mediated MPGN due to abnormalities caused in the function and regulation of 
the alternative complement pathway. (1)  Complement mediated MPGN is then classified 
into C3 glomerulonephritis and DDD but due to the transition noted between C3 
glomerulonephritis and DDD on electron microscopy, they probably represent a 
morphologic spectrum due to the underlying alternative complement pathway 
dysregulation. (9) The diagnosis should be focused on the assessment of the alternative 
pathway and mutations or antibodies to the complement binding proteins. (9)   
 
MPGN type I and type III are now classified as immune complex mediated as they include 
both immunoglobulin deposition and complement deposition. (9) It is then further divided 
into the MPGN associated with chronic infections, autoimmune disease and monoclonal 
gammopathy. Hepatitis C and infrequently hepatitis B are the chronic viral infections 
attributed to the antigen antibody complexes deposited in immune complex mediated 
MPGN, while chronic bacterial infections such as endocarditis, infected ventriculo-atrial 
shunts, visceral abscesses, leprosy and meningococcal meningitis are also attributed. (9) 
Other suggested infections that cause immune complex mediated MPGN are malaria, 
schistosomiasis, mycoplasma and leishmaniasis. (9) The commonest autoimmune diseases 
that result in increased immune complexes are systemic lupus erythematosus, Sjogren’s 
syndrome and rheumatoid arthritis. (9) Lastly, immune complex mediated MPGN is 
secondary to monoclonal gammopathies including the monoclonal gammopathy associated 
MPGN. (9) There is a small allowance made that if none of the aforementioned conditions 
exist, then it is labeled idiopathic MPGN. (9)  
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This classification thus excludes what was previously described as familial MPGN type I 
and type III. To further complicate matters, C3 glomerulonephritis with subepithelial 
deposits may be labeled MPGN type I, while C3 glomerulonephritis with intramembranous 
and subepithelial deposits may be labeled MPGN type III, (9) yet with the new 
classification they are identified as complement mediated MPGN, distinct from Type I and 
III now classified as immune mediated MPGN. (9) 
 
Epidemiologically, MPGN is a rare cause of glomerulonephritis and accounts for 7% of 
adults (10) and 4-7% of children (2) with a primary renal cause of nephrotic syndrome and 
accounts for 7-10% of biopsy proven glomerulonephritis. (1) The familial incidence has 
been described as 2.6- 4% in primary MPGN type I and type III.  (5)  A familial form of 
MPGN type III has been identified with an autosomal dominant pattern of inheritance that 
is genetically linked to band 1q31-32.  (4)  The mode of inheritance has not been 
adequately established, with current suggestions being autosomal dominant, x-linked 
pattern of inheritance and autosomal recessive.  (6,7)  Although familial forms of MPGN 
type I, type II and type III disease have been reported previously, none of these reported 
families have been South African. 
 
From 1976-2014 familial MPGN type I and III was reported in 30 patients. This diagnosis 
was established after excluding other causes of MPGN and the type of MPGN was 
confirmed on light microscopy (LM) and the type was based electron microscopy (EM) 
findings.  In the first study Berry et al. (11) presented two unrelated sibships. All four 
patients presented within the first decade of life with proteinuria and hypertension.  
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In the first family “The M siblings” the brother (JM) was found to have MPGN type III on 
LM and EM and on immunoflourscence there was moderate deposition of C3 and a small 
amount of IgG. His sister (PM) had MPGN type I on LM and EM and on 
immunoflourscence there was marked deposition of C3 and a small amount of IgG. The 
serum C3 levels were low for both siblings at diagnosis, however PM’s serum C3 had 
normalised at the time of publication. Both siblings were treated and maintained on 
alternate day prednisone. They had improved clinically by the time of the article’s 
publication.(11) 
Figure 4: Pedigree M family Berry et al.
Figure 5: Pedigree G family Berry et al.
JM PM
Unaffected
Affected
Gender unknown
WG KG
 
 
The second sibship were labeled as “The G siblings”. They were two brothers who were 
discovered incidentally when WG was found to be anaemic, hypertensive and proteinuric 
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on a routine preschool physical examination. His bother KG had previously been anaemic, 
was then worked up for renal disease and was found to have severe renal dysfunction. 
Neither brother had haematuria. Both were found to have MPGN type I on LM and EM, 
and on IFM they were both found to have marked IgM and IgG deposition.  
 
KG had marked C3 deposition while WG had minimal C3 deposition. However the biopsy 
available from KG was the biopsy done 4 years after presentation and not the initial 
biopsy. Throughout their diagnosis and followup, both brothers’ serum C3 levels remained 
normal. Both brothers were placed on therapy with alternate day prednisone. However 
their hypertension worsened on therapy and they both had a slow decline in renal 
function.(11) 
 
The conclusions drawn by Berry et al. (11)  was that there was likely an underlying genetic 
basis for the disease but that exposure to certain enviromental factors would result in 
disease expression. Due to the different types of MPGN in the sibship of the M family, 
they postulated that MPGN is multigenic in origin, modified by other genes which regulate 
the immune responses resulting in the different types of disease expression. (11)  
Interestingly in the G family, KG and his faher had C2 deficiency. However KG has an 
affected brother who  was not C2 deficient and his father, who was C2 deficient, had no 
disease. This indicated that in this family the C2 deficiency was not associated with a 
predisposition to MPGN (11) as previously shown by Kim et al.(12) 
 
Stutchfield et al. (13)  reported two related male patients with type 1 MPGN and they 
surmised that the inheritance was an x-linked recessive disorder. Both patients were 
proteinuric and presented within the first two years of life. The first patient (LA) presented 
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with persistent proteinuria originally detected on routine urine testing. He was found to be 
normotensive and had no haematuria. He had normal renal function as well as normal 
serum C3 levels. He later developed hypertension and had slowly deteriorating renal 
function. His serum C3 level however remained consistently normal. On renal biopsy the 
LM and EM findings were consistent with MPGN type 1. On immunofluorescence he had 
depositis of IgG, IgM and minimal C3.(13) 
 
NH
LA
RT
IT
JH
CAJC
Unaffected
Demised
MPGN Presumed
Affected
Figure 6: Pedigree of family Stutchfield et al.
 
 
The second patient (NH), the maternal uncle of the first patient (LA), presented with 
bipedal oedema and persistant proteinuria. He was normotensive, had microscopic 
haematuria and normal renal function. He was also found to have normal serum C3 levels. 
The renal biopsy features were that of MPGN type 1 on LM and EM. Immunofluorescence 
however was not done. He received cyclophosphamide but the proteinuria persisted and his 
renal function gradually deteriorated. He later became hypertensive. Throughout his course 
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his serum C3 and C4 levels remained normal. He demised from hypertensive 
encephalopathy.(13) 
 
In terms of the family’s pedigree, the grandmother (JH) of LA, the mother of NH, had only 
one son (NH) who  had biopsy proven MPGN. However her two other sons from different 
fathers demised at a young age following nephritic illnesses. Her daughter (CA), a half 
sister to NH, and the mother to LA, was healthy. Four of the grandmother’s (JH) ten 
brothers died at a young age, with two having symptoms suggestive of  nephritic/nephrotic 
illness. Furthermore, one of the grandmother’s (JH) sisters had a son who also died in the 
first decade of life from a similar illness. This was the first study with patients diagnosed 
with MPGN under the age of two, reflecting an underlying genetic basis for the disease. 
Together with the family pedigree an assesment was made of the mode of inheritance 
being x-linked recessive.(13) 
 
Sherwood et al. (14) described a father and son with MPGN, that the authors describe as an 
autosomal dominant pattern of inheritance. The son at the age of four, was found to have 
proteinuria on admission for a tonsillectomy. He was normotensive, had haematuria and 
normal serum C3 and C4 levels. Renal ultrasound was normal and he also had normal 
renal function at diagnosis. A renal biopsy was done when the son was 5 years old. While 
on LM and EM the features were consistent with MPGN type I, immunofluorescence was 
however negative for IgG, IgA, IgM and C3. His condition remained stable and he was not 
receiving any treatment.(14) 
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Son
FatherAffected
Unaffected
Figure 7: Pedigree of family Sherwood et al.
 
 
His father at the age of twenty two years was found to be proteinuric and hypertensive. He 
had a renal biopsy eight years later when he had end stage renal failure, which on LM and 
EM had features of end stage renal disease due to MPGN. The type of MPGN was not 
mentioned. Three years later at the age of thirty three, the father underwent renal 
transplantation. No information is supplied regarding serum C3 and C4 levels, nor 
regarding his treatment. Both father and son were found to have unusual facies as well as 
unusual telangiectasia not associated with any known syndrome. The final conclusion from 
the authors was that the mode of inheritance for this family was autosomal dominant. They 
distinguished their family from the previous study by Stutchfiel et al. due to the unusual 
skin condition seen in father and son.(14) 
 
Bakkalogu et al. (7)  described six patients from two families with MPGN. Family one (G 
family) had first-degree consanguinity in the parents. All four sons were affected.The two 
daughters and parents were unaffected. All four of the affected sons presented within the 
first decade of life with proteinuria. Two (SG and AG) had hypertension at diagnosis and 
one son (BG) developed hypertension during the course of the disease. The youngest son 
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(IG) presented at the age of 10 months. Two of the brothers (SG and BG) presented at the 
age of three years and the other brother (AG) was seven years old at diagnosis. All had 
normal renal function at diagnosis, however the patient AG had progressive worsening 
renal function at the time of publication. All four brothers had normal serum C3 and C4.  
 
Only three of the brothers’ biopsy results were available as the eldest brother (AG) had had 
the diagnosis of MPGN made previously. Of the three biopsies, all were in keeping with 
MPGN type I. In the patient SG, no immunoflourescence was done. In the other two 
brothers (BG and IG), there was mainly C3 deposition. One of the father’s (DG) brothers 
died of an illness suggestive of nephritic syndrome; no further information was available 
about this family member. (7)  
 
IGHGAGSGBGKG
TG DG MG CG ZG NG
Unaffected
Demised
MPGN Presumed
Affected
Figure 8: Pedigree of the G family Bakkalogu et al.
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The second family “The Y family” had unrelated parents and four sons and one daughter. 
Two brothers presented with hypertension, proteinuria and haematuria at the age of nine 
(MY) and thirteen (FY). Their initial serum C3 and C4 levels were low but subsequently 
normalised. On biopsy, the LM and EM finding were consistent with MPGN type I and on 
immunoflourescence, MY had only C3 deposition while FY had C3 and IgA deposition. 
No abnormalities were detected in the serum complement profile in both families. On 
review of both families, the mode of inheritence is proposed to be autosomal dominant or 
an X-linked inheritance with incomplete penetrance, as members in more than one 
generation were affected. However there was a different progression of disease between 
MY and FY which the authors postulated as indicating a multigenic orgin for MPGN, with 
a gene predisposing to MPGN but requiring modification by other genes affecting immune 
control, resulting in the different modes of disease expression (7) , a similar finding to that 
of Berry et al.(11) 
 
Abderrahim et al. (15)  reported two brothers who were both diagnosed with MPGN I. 
There was first degree consanguinity in the parents. The first patient HL presented at the 
age of 17 with hypertension, bilateral pitting oedema, proteinuria and macroscopic 
haematuria. He had a normal renal ultrasound and normal serum C3 and C4 and mild renal 
dysfunction. His renal biopsy on LM and EM was consistent with MPGN type I. There 
was no comment made regarding immunoflourescence. HL was started on antiplatelet 
agents and beta blockers. Eighteen months later his renal function had normalised and he 
had trace proteinuria. His complement levels were normal.(15) 
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Unaffected
MPGN Biopsy proven
HLHA
Figure 9: Pedigree of family Abderrahim et al.
 
 
HL’s elder brother HA presented with hypertension, haematuria and proteinuria at the age 
of eighteen. His renal biopsy findinging on LM and EM were in keeping with MPGN type 
I. He had renal failure at diagnosis and demised three years later from end stage renal 
disease. Limited data is available regarding HA as he was diagnosed and treated at a 
different hospital than that of the authors. Regarding the presentation and progress of the 
two brothers, the authors postulated that familial MPGN is a multifactorial disease. (15) 
 
Bogdanovic et al. (5)  reported two siblings with MPGN. Patient 1 was a boy who was 5 
years old when he presented with bipedal oedema, hypertension, haematuria and 
proteinuria. He had low serum  C3 and C4 levels. LM and EM findings were of MPGN 
type I. Immunoflourescence showed IgG, IgM, IgA and C3 deposits. Initally he was started 
on alternate day prednisone, followed by cyclosporine and then cyclophosphamide. His 
nephrotic syndrome resolved when he was nine, but he remained with residual proteinuria. 
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Patient 1 Patient 2
Unaffected
Affected Biopsy proven
Chronic Pyelonephritis
Figure 10: Pedigree of family Bogdanovic et al.
 
 
Patient 2 was a girl who presented only with proteinuria when she was at the age of 3 
years. Her disease progressed and when she was six years old, she presented with 
nephrotic syndrome. Her serum C3 and C4 levels were persistently normal.  On LM and 
EM, she had findings in keeping with MPGN type III. She had C3, IgG, IgM and IgA 
deposits on immunoflourescence. She received the same treatment as her brother, but she 
remained nephrotic and her renal function declined at the age of seven and a half years. 
 
In terms of the family history, the parents were unrelated and the father was healthy. The 
mother developed hypertension and advanced renal failure at the age of eighteen during 
her first pregnancy, which was terminated by miscarriage. Her renal function declined and 
three years later regular haemodialysis was started. Her renal failure after workup was 
attributed to chronic pyelonephritis. She was transplanted at the age of tewnty-two and her 
graft renal function was excellent. She went on to deliver her two children post 
transplantation. Autosomal dominant disease possibly associated with MPGN was 
excluded in this family. (5)  
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The authors reviewed the other families previously published with MPGN and found no 
reported abnormalities of complement which corresponded with their patients. They also 
found that different HLA haplotypes were associated with MPGN in the different studies. 
The highest frequency was that of HLA-A2. However, previously it was noted that patients 
with haplotype HLA-B8 had a poorer prognosis for kidney function. However, their 
patients had  HLA-A24, B27, Bw4, DR11, DR52 and DQ3 in common, and while having 
similar clinical pictures, they had different types of MPGN and despite the same treatment, 
they had markedly different outcomes. Thus, their finding was that the mode of inheritance 
is probably multigenic in orgin, with an underlying gene predisposing to MPGN but 
modified by other genes. (5)  
 
Motoyama et al. (6)  published a case report of MPGN type I diagnosed in a mother and 
her daughter. Case 1, the daughter at the age of fourteen, had microscopic haematuria and 
proteinuria detected on routine school urinary testing. She was normotensive and had low 
serum C3 levels, but normal C4 levels. LM findings on biopsy were that of MPGN type I. 
No glomeruli were included in the specimen for EM. On immunoflourescence there were 
only C3 deposits. She was treated with methylprednisone for three days followed by 
prednisone. The proteinuria disappeared and the prednisone was stopped in a month. She 
continued to have microscopic haematuria and hypocomplementaemia. (6)  
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Figure 11: Pedigree of family Motoyama et al.
 
 
Case 2, the mother, developed oedema, hypertension, proteinuria, and microscopic 
haematuria when she was nine years old. Both serum C3 and C4 levels were low. The 
oedema and hypertension improved a month later but the haematuria, proteinuria and 
hypocomplementaemia persisted. The renal biopsy findings on LM and EM were in 
keeping with MPGN type  I and on immunoflourescence, only C3 deposits were found. 
She was started on steroid therapy but continued to have proteinuria. She defaulted therapy 
at the age of fifteen and presented again at the age of twenty four, when she was found to 
be normotensive, with no oedema but persistent proteinuria. She had low serum C3 and 
normal serum C4 but mild renal dysfunction.  
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She was started on dipyridamole and had three successful pregnancies, but developed 
nephrotic syndrome in the first and third pregnancies. During the last pregnancy her renal 
function declined and she received methylprednisone and her renal function improved. At 
the time of publication she had normal renal function with low serum C3 and mild 
proteinuria. Only one of her daughters had MPGN type I, the other children were healthy. 
The authors postulated that the mode of inheritance is unclear, and while there may be an 
underlying genetic basis, it is likely that enviromental factors are a cause, due to the 
discrepencies in clinical and pathological findings in family members. (6)  
 
The last two familial studies are both from Ireland. The first family described by Neary et 
al. the index case (subject 105), a 51 year old male, presented with hypertension, 
haematuria, proteinuria and renal dysfunction. Twelve years earlier he had been healthy 
with no haematuria or proteinuria on donation of a kidney to his son (subject 213). While 
his complement profile was normal, his renal biopsy on LM had features consistent with 
MPGN and EM features suggested it to be of type III. On IFM there was only C3 
deposition. He was treated with steroids and pulsed with cyclophosphamide and still has 
persistent renal dysfunction. 
 
His son had presented at the age of four years with nephrotic syndrome unresponsive to 
steriods. He also had a low serum C3 and normal C4 and was found to have microscopic 
heamaturia. His renal biopsy on IFM showed C3 deposition and on EM the MPGN was 
listed as type III MPGN with subendothelial, intramembranous and subepithelial basement 
membrane depositis. Six years later, at the age of ten years he received a kidney transplant 
from his father for ESRD. On a renal biopsy specimen of the transplanted kidney, two 
years after transplant, the speciment showed MPGN type III with C3 deposition on IFM. 
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Six years post transplant he developed graft failure and receieved a second graft. It is not 
stated whether it was cadaveric or familial tranplant. Up to publication he was doing well 
but remained proteinuric. 
 
His brother (subject 212) and sister (subject 214) were investigated for nephrotic 
syndrome. Both of their renal biopsy specimens were in keeping with MPGN type I. Both 
had normal serum complement levels and normal renal function. Their paternal aunt  
(subject 103) also developed ESRD at 51 years of age and her biopsy, done at the age of 
twenty-six years, was also consistent with MPGN. She was found to have normal serum 
complement and received a renal transplant at the age of fifty-four years. 
 
The index patient’s sister (subject 107) and niece (subject 223) , on screening were found 
to have haematuria and proteinuria and on renal biopsy MPGN type III. They both also had 
normal serum complement levels.  
 
Neary et al. in a follow up study of this study found a linkage of chromosome 1q to MPGN 
type III with an autosomal dominant pattern of inheritance. (4)  This locus was found to 
contain genes that code regulators of the complement pathway. The authors concluded that 
MPGN type III was more likely to be steroid resistant and typically progressed to ESRD 
within ten years after presentation. (4)  
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Redahan et al. described 3 separate families all with familial MPGN, however the third 
family was diagnosed with MPGN of dense deposit disease type (type II MPGN) and thus 
is excluded from this study. The first family had two affected members.  
 
The index case was 16years of age when she presented in renal failure. She had no other 
medical history and on renal biopsy was found to have MPGN with immune complex 
deposition. Within five years she had progressed to ESRD and was initiated on RRT. She 
received a cadaveric transplant a year later at the age of 22 years which failed due to 
chronic allograft nephropathy, which also caused the failure of her second cadaveric 
transplant. Her third graft remained well functioning at time of the publication. No 
evidence of recurrence was found in any of the grafts. 
 
Her brother was diagnosed with renal disease at the age of eighteen and his biopsy showed 
MPGN with immune complex deposition. He received a cadaveric transplant at the age of 
twenty two years after starting RRT at the age of twenty-one years.(16) 
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The second family’s index case was a twenty-two year old male (case2A) who presented 
with a severe headache, hypertension and renal dysfunction. He was found to have 
haematuria, proteinuria and low serum complement levels. On renal biopsy he was found 
to have a moderate amount of immunoglobulin and complement deposition. Within twelve 
months he had progressed to ESRD and started RRT. A year later he received a kidney 
transplant from a living related donor, one of his siblings.(16) 
 
A routine examination of the youngest brother (case 2B) revealed proteinuria and a renal 
biopsy was done, which demonstrated MPGN with immunoglobulin and complement 
deposition. At seventeen years of age he received a kidney transplant from one of his 
siblings, although it was done preemptively. Six years later he received a second 
transplant, from another sibling, after graft failure occurred due to disease recurrence. The 
second eldest brother (case 2C) developed microscopic haematuria at the age of thirty-one 
years and underwent a renal biopsy with had features of an IgA nephropathy. He however 
remained well and didn’t progress in terms of his renal disease. Redahan et al then 
discusses the possible inheritance pattern of family 1 as autosomal recessive and family 2 
as x-linked or autosomal recessive.(16) 
 
From the above, it can be seen that very few families world wide have been described with 
familial MPGN and none have been South African. Futhermore, since the new 
classification of MPGN has come into place, there is increasing confusion as to which 
category familial MPGN falls into. By examining this South African family and doing a 
systematic review of the literature, a larger case series is obtained which allows for an 
improved understanding of the conundrum that is familial MPGN type I and Type III. 
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AIMS 
 
 
 
1. The aim of this study is to determine the incidence of MPGN within the family of 
our index patient as well as to assess if there is a Mendelian inheritance pattern 
within this family.  
2. Further more a systematic review was undertaken to review the available literature 
on familial MPGN and to classify familial MPGN within the new definitions of 
MPGN. 
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OBJECTIVES 
 
 
1.  Determine the incidence of MPGN within the family of our index patient. 
2.  Assess the Mendelian inheritance pattern within this family 
3.  Review and compare with previous published studies. 
4.  Classify familial MPGN 
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METHODS  
 
Ethical Approval 
 
Ethics approval was obtained from the Human Research Ethics Committee (Medical) of 
the University of the Witwatersrand, certificate number M120446, for a prospective study 
of the available family members of the index patient and a retrospective study of those 
family members already worked up or diagnosed and been treated for MPGN type1.  
 
Study Population 
 
All contactable family members of the index patient that consented to participate in the 
study were included. The four family members, including the one deceased family 
member, that attended the Renal Unit at the Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) were also included as part of the retrospective study.  
 
Data Collection  
 
The study was an open study with the primary investigator knowing the results for all 
participants included in the study. With regards to the data collection, each participant was 
given a coded number and all data collected was kept under this code to maintain 
confidentiality, with only the primary investigator knowing the coding system. 
 
The data collected from the Renal Unit at CMJAH for those family members already 
worked up for the disease, included the patient’s history, clinical presentation, blood 
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results as well as their renal biopsy results. All other asymptomatic contactable family 
members that consented to participate in the study were included and participants provided 
a urine sample, which was tested for proteinuria and haematuria with Uricheck M10 Urine 
Reagent Strips Omnipharma (Pty) Ltd.  
 
Histories were obtained from the asymptomatic family members to determine if other 
diseases and comorbidities were present that would affect the results. If a co-morbidity was 
found, they were excluded from the study. A blood sample in an EDTA tube was also 
taken and kept at minus 20 degrees Celsius for DNA extraction for a follow up study to 
assess if there is an underlying genetic mutation within this family. If family members 
were found to have proteinuria and/or haematuria with no other cause for the proteinuria 
and/or haematuria, they were considered positive for this study and referred for further 
work up including a renal biopsy at CMJAH Renal Unit. The data obtained from family 
members diagnosed with MPGN was collated with the information available from previous 
reports. 
 
Systematic review 
 
For the Systematic review, the two following terms were searched in PubMed separately, 
familial MPGN and inherited MPGN. The term mesangiocapilliary is used interchangeably 
for MPGN on PubMed, and using the term mesangiocapilliary glomerulonephritis in place 
of MPGN has the same results as for the MPGN search. Combining the two searches, 
ninety-seven articles were found but only ten were applicable. The eighty-seven articles 
that were excluded pertained studies regarding animal MPGN studies, Type II MPGN 
(DDD) or C3 nephropathy, and studies that were MPGN associated with other illnesses 
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including those associated with haemolytic uraemic syndrome and familial Mediterranean 
fever. The reports that did not include actual familial studies in the research report were 
also excluded. Of those ten articles that were applicable, two were concerning the same 
family  (4,17) , one study was a descriptive study (17) and the other looked at the genetics 
pertaining to the family studied. (4)  Reports of MPGN in siblings prior to 1980 had very 
limited data especially regarding the biopsy results and immunofluorescence and as such 
they were unable to be reclassified according to the new definitions of MPGN and thus 
were also excluded.  
 
A Spanish study by Robles et al. (18)  appeared to be applicable, however all attempts to 
obtain the study including writing to the authors has been unsuccessful. The studies that 
were applicable and able to be obtained were assessed and their data combined and where 
possible reclassified according to the immunofluorescence results. In the report by 
Redahan et al. (16)  Family 3 was excluded from the systematic review as the family 
members were diagnosed with MPGN type II which was an exclusion criteria for the 
systematic review. 
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RESULTS 
 36 
The Study Family 
 
17 of the 20 contactable family members were available and consented to participate in the 
study. Four members (22%) were affected. The three who were proteinuric and without 
any comorbidities were the three members currently attending the renal unit at CMJAH. 
The demographics and clinical presentation of the affected family members can be found 
in table 1. Their family tree can be found in figure 10. 
 
 
Our index patient (413) presented to the renal unit at CMJAH at the age of seventeen with 
nephrotic syndrome. At the age of thirteen years, she had presented at another institution 
with bipedal oedema, hypertension and proteinuria and was diagnosed with nephrotic 
syndrome secondary to idiopathic MPGN type I and had been on oral steroids (prednisone 
5mg alternate days) since then. Despite the corticosteroid use, she remained proteinuric 
Table 1: Demographics and clinical data 
Patient Designation 304 405 404 413* 
Gender Male Male Male Female 
Age at diagnosis 
(years) 
29 15 18 13 
Follow up (years) 1 8 5 8 
Hypertension Yes No No Yes 
Hypertensive at follow 
up 
Yes Yes No Yes 
Haematuria Yes Yes Yes Yes 
Persistant Haematuria Yes Yes Yes Yes 
Proteinuria Yes Yes Yes Yes 
Urine protein g/24hr 4.9 14.0 10.4 3+ ** 
Persistant Proteinuria Yes Yes Yes Yes 
ESRD age 
Demised 
before follow 
up 
19 No No 
Table with the patient demographics, clinical presentation, residual clinical 
characteristics and age at diagnosis of end stage renal disease (ESRD) IP: Index Patient 
* Index patient; **only data from qualitative urinanalysis available as patient previously 
diagnosed at another institution. 
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and was admitted by the renal unit at CMJAH for a repeat renal biopsy. The rest of her 
medication included perindopril 8mg daily, telmisartan 40mg daily and atorvastatin 20mg 
daily. She had normal renal function at both renal biopsies and her serum C3 and C4 levels 
have always remained normal. She had no co-morbidities her initial lab results can be 
found in table 2. 
 
Table 2: Laboratory data 
Patient Designation 304 405 404 413* 
Serum Creatinine umol/l 238 97 71 14 
Serum Albumin g/l 16 34 39 26 
Serum C3 Normal Normal Normal Normal 
Serum C4 Normal Normal Normal Normal 
GFR at diagnosis mL/min 32 71 128 182 
Creatinine at follow up 
umol/L 
265 906 93 170 
GFR at follow up mL/min 29 8 96 40 
Table with the laboratory data pertaining to the affected family members 
* Index patient; 
 
 
The light microscopy and immunofluorescence features of her renal biopsy were in 
keeping with an immune-complex mediated glomerulonephritis with a 
membranoproliferative reaction pattern favoured to represent those of MPGN type I.  As 
shown in table 3, she had IgG and C3 deposition on IF thereby reclassifying her as an 
immune-complex mediated MPGN. All other causes of proteinuria were excluded as well 
as other causes of immune-complex mediated MPGN. Despite immunosuppressive 
treatment (tacrolimus and glucocorticoids at higher doses) her renal function continued to 
steadily decline to a glomerular filtration rate (GFR) of 40mL/min (originally 182mL/min) 
and she remained proteinuric. She did not develop any complications post biopsy nor from 
her treatment. 
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Table 3: Renal Biopsy Features and MPGN Classification 
Patient 
Designation 
Classification at 
diagnosis 
Immunofluorescence Microscopy New 
Classification IgG IgM C3 
304 MPGN Not done Not done Not done 
IM features on 
light microscopy 
405 MPGN TYPE I Yes Yes Yes IM 
404 ATN No No No ATN 
413* MPGN TYPE 1 Yes No Yes IM 
Table with the renal biopsy features and the original diagnosis made with the old 
classification and the new classification based on the biopsy results. * Index patient; 
ATN: Acute tubular necrosis; IM: Immune complex mediated 
 
Two of her first cousins (404 and 405) who are brothers, and her one maternal uncle (304) 
had also attended the renal unit at CMJAH. Her two cousins were from a consanguineous 
marriage, with their parents being first cousins. 405 presented prior to his brother (404) to 
the CMJAH paediatric unit, at the age of 4 years, with jaundice and splenomegaly 
following an acute hepatitis A infection. On a follow up visit at 11 years of age, he was 
found to have asymptomatic microscopic haematuria and he was referred to CMJAH 
paediatric renal unit.  
 
He remained asymptomatic and all workup was normal, a renal biopsy was not done. He 
then moved to Cape Town. At the age of 15 years, he returned to the paediatric unit at 
CMJAH with anasarca and hypertension and was found to have marked proteinuria and 
haematuria and was worked up for nephrotic syndrome. He had normal serum C3 and C4 
levels and a normal GFR. All other work up for his nephrotic syndrome was negative. He 
also tested negative for all causes of immune-complex mediated MPGN. He had a normal 
renal and abdominal ultrasound and the portal hypertension and splenomegaly, previously 
diagnosed at four years of age, had all resolved and were normal. 
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His renal biopsy’s histological features were in keeping with an immune-complex 
mediated glomerulonephritis with a membranoproliferative pattern and a mild to moderate 
acute tubular necrosis. The electron microscopy findings were supportive of an immune 
complex mediated MPGN type 1. IFM showed marked IgG deposition, IgM and C3 
staining thereby his new classification was thus immune-complex mediated MPGN.  
 
He was started on daily oral prednisone at 1mg/kg and had three cycles of 
cyclophosphamide, which resulted in resolution of the haematuria and a decrease in the 
proteinuria although he still remained proteinuric. The oral prednisone was then weaned 
and stopped after 11 months of treatment. Seven months later he was then restarted on oral 
prednisone and Mycophenolate Mofetil (trade name: Cell Cept) 500 mg daily as his 
proteinuria had increased and he was transferred to the adult renal unit at CMJAH. Despite 
immunosuppressive treatment he remained proteinuric and had a progressive decline in 
renal function ultimately resulting in end stage renal disease (ESRD) four years after 
diagnosis. He is currently on renal replacement therapy and awaiting renal transplantation. 
 
404, brother to 405, presented at the age of nineteen years with nephrotic syndrome. His 
renal function was normal at the time and his serum C3 was slightly raised and he had a 
normal serum C4. His work up for all causes of nephrotic syndrome was negative and he 
had a normal renal and abdominal ultrasound. On renal biopsy LM and EM features were 
in keeping of an acute tubular necrosis (ATN). On immunofluorescence there was no 
complement and immunoglobulin deposition staining. Despite extensive workup, no cause 
of the ATN was found and a final assessment of mild acute tubular necrosis of unknown 
cause was made. He however continued to have proteinuria and was started on daily 
prednisone at 1mg/kg. The proteinuria gradually decreased and after the fourteen month, 
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the prednisone was stopped. His blood pressure also normalized on treatment. After the 
prednisone was stopped he has followed up at the renal unit irregularly due to work 
commitments.  
 
In 2013 he returned to the unit and was found have mild proteinuria and his GFR has 
steadily declined. At a previous visit, his GFR had been lower than his original GFR but no 
follow up occurred due to the patient being lost to follow up. His GFR has been steadily 
declining, although not at the same rate as his younger brother, and his most current GFR 
is 93ml/min (original GFR at presentation was 128ml/min). Due to his work commitments, 
he was unable to attend the renal unit regularly and there has been a delay in obtaining a 
repeat renal biopsy. In light of the fact that he presented with nephrotic syndrome and the 
biopsy results, despite being reviewed, were out of keeping with his nephrotic syndrome 
and as currently he remains proteinuric , he is undergoing active work up again for a repeat 
renal biopsy. 
 
Six years earlier 304, the maternal uncle of our index patient, was referred to CMJAH 
at the age of twenty nine years after presenting to a private health care facility where 
he was diagnosed with nephrotic syndrome with renal failure. He was unemployed 
and had no funds for medical care and hence he had not sought medical care sooner.  
He was hypertensive and had anasarca. There were no other abnormalities noted on 
examination. He had normal serum C3 and C4 and on history had no co-morbidities. 
On renal biopsy, only a single core of tissue was submitted and sent for light 
microscopy. Histopathology did not receive any tissue specimens for 
immunofluorescence microscopy and electron microscopy. LM findings of the renal 
biopsy were in keeping with an immune-complex mediated diffuse proliferative 
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glomerulonephritis with a membranoproliferative reaction pattern, typical for the 
diagnosis of MPGN. As specimens for IFM were however not submitted it was difficult 
to distinguish between MPGN type I and type III.  
 
He was started on cyclophosphamide and oral prednisone and his GFR increased to 
63mL/min (previously it was 32mL/min. He developed Escherichia coli sepsis after 
the cyclophosphamide dose. He improved on antibiotics and was discharged home. 
Two months later, on admission for the second cycle of cyclophosphamide, his GFR 
had decreased again now to 31mL/min and he presented with anasarca, seizures and 
pulmonary oedema. He was started on renal replacement therapy, which was stopped 
just prior to discharge as his renal function had again improved after the 
cyclophosphamide was given. A few months later he suddenly demised. 
Unfortunately no documents could be traced regarding the events leading up to his 
death. However, after discussion with his relatives, myocardial infarction seems the 
most likely cause of his death. 
 
Three other family members (102; 201; 202; 305) demised from renal disease in their 
fourth decade of life. Although the formal diagnosis is unknown, based on the history 
described by family members, MPGN is suspected. 
 
The inheritance pattern does not appear to be a clear Mendelian pattern. The two brothers 
were from a consanguineous marriage that would suggest autosomal recessive, however 
more male family members are affected which would suggest x-linked recessive, but that 
does not account for the female family members. Also in other consanguineous marriages, 
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no siblings were affected. This suggests while there is a definite underlying genetic basis, 
it is either autosomal recessive with incomplete penetrance or multigenic.
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Systematic review Results 
The nine reports contained information regarding twelve families that combined with this 
study’s family takes the number to thirteen families with thirty-four family members. 
There is a definite male predominance with twenty-five being male and only nine being 
female. The mean age was fifteen years, with a median of fourteen years and a mode of ten 
years at diagnosis. The eldest family member was fifty-one years at diagnosis. The age 
range was forty-eight years with a standard deviation of nine years. Table 4 contains the 
demographics of the family members. The mean follow up was six years. The mean 
creatinine at diagnosis was 134umol/L with a median of 66umol/L and a mode of 
53umol/L. The mean age at which ESRD occurred was twenty-three years, with a median 
and mode of twenty-one years. The clinical presentation was mainly that of nephrotic 
syndrome with hypertension and proteinuria (table 5). 
 
Table 7 contains the biopsy results and the previous MPGN classification as well as the 
new classification. In those family members where immunofluorescence was not 
performed, the same classification was given as the other members of their family. From 
this, it is noted that two distinct groups form; one that is complement-mediated and the 
other that is immune complex mediated, which the South African family falls into. The 
two groups are split from this point on. The studies by Sherwood et al. and Abderrahim et 
al. have too little information to be able to reclassify these families and thus they are not in 
the subdivided groups of immune complex mediated and complement-mediated. 
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Table 4: Demographics 
Author Reference 
Patient 
Designation 
Gender 
Age at 
Diagnosis 
(years) 
Follow up 
(years) 
Age at ESRD (years) 
Berry et al. (11)  JM Male 10 5 No 
Berry et al. PM Female 9 2 No 
Berry et al. WG Male 5 4 No 
Berry et al. KG Male 7 5 No 
Strutchfield et al. 
(13)  
LA Male 1yr 9months 2 No 
Strutchfield et al. NH Male 1yr 5 months 6 5 Demised 
Sherwood et al.  Father Male 22 8 30 
Sherwood et al. Son Male 4 1 NR 
Abderrahim et al. HI Male 17 2 No 
Abderrahim et al. HA Male 18 3 21 
Bakkaloglu et al. SG Male 3 1 NR 
Bakkaloglu et al. AG Male 10 7 10 
Bakkaloglu et al. BG Male 3 6 NR 
Bakkaloglu et al. IG Male 10 1 NR 
Bakkaloglu et al. MY Male 9 4 NR 
Bakkaloglu et al. FY Male 13 2 NR 
Bogdanovic et al. SC Male 5 5.5 No 
Bogdanovic et al. MC Female 5 yr. 6 months 3 8.5 
Motoyama et al. Case 1 Female 14 1 NR 
Motoyama et al. Case 2 Female 9 31 NR 
Redahan et al. 1A Female 16 22 21 
Redahan et al. 1B Male 18 13 21 
Redahan et al. 2A Male 22 2 23 
Redahan et al. 2B Male 15 2 17 
This Report 304 Male 29 1 29 Demised 
This Report 405 Male 15 8 19 
This Report 404 Male 18 5 No 
This Report 413* Female 13 8 No 
Neary et al. 213 Male 4 NR 10 
Neary et al. 105 Male 51 NR No  
Neary et al. 212 Male 28 NR No 
Neary et al. 214 Female 21 NR No 
Neary et al. 103 Female 25 NR 54 
Neary et al. 223 Female 16 NR No 
Mean   15 6 23 
Median   14 4 21 
Mode   10 2 21 
Standard Deviation   
9,85 
 
6,77 
 
12,51 
 
Table containing the demographics of all affected family members:  
ESRD: End Stage Renal Disease * Index patient 
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Table 5: Clinical presentation 
Author Reference 
Patient 
Designation 
Hypertension Haematuria Proteinuria 
Berry et al. JM Yes Yes Yes 
Berry et al. PM Yes Yes Yes 
Berry et al. WG Yes No Yes 
Berry et al. KG Yes No Yes 
Strutchfield et al. LA No No Yes 
Strutchfield et al. NH No Yes Yes 
Sherwood et al. Father Yes NR Yes 
Sherwood et al. Son No Yes Yes 
Abderrahim et al. HI Yes Yes Yes 
Abderrahim et al. HA Yes Yes Yes 
Bakkaloglu et al. SG Yes NR Yes 
Bakkaloglu et al. AG Yes NR Yes 
Bakkaloglu et al. BG No NR Yes 
Bakkaloglu et al. IG No NR Yes 
Bakkaloglu et al. MY Yes NR Yes 
Bakkaloglu et al. FY Yes NR Yes 
Bogdanovic et al. SC Yes Yes Yes 
Bogdanovic et al. MC No Yes Yes 
Motoyama et al. Case 1 No Yes Yes 
Motoyama et al. Case 2 Yes Yes Yes 
Redahan et al. 1A NR NR NR 
Redahan et al. 1B NR NR NR 
Redahan et al. 2A Yes Yes Yes 
Redahan et al. 2B NR NR NR 
This Report 304 Yes Yes Yes 
This Report 405 No Yes Yes 
This Report 404 No Yes Yes 
This Report 413* Yes Yes Yes 
Neary et al. 213 Yes No Yes 
Neary et al. 105 Yes Yes Yes 
Neary et al. 212 Yes Yes Yes 
Neary et al. 214 No Yes Yes 
Neary et al. 103 Yes NR Yes 
Neary et al. 223 Yes Yes Yes 
Table depicting the clinical presentation of all the family members  
* Index patient 
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Table 6: Laboratory Data 
Author Reference 
Patient 
Designation 
Serum Creatinine 
umol/l 
Serum Albumin g/l Serum C3 Serum C4 
GFR at 
diagnosis 
Berry et al. JM 27 18 Decreased NR NR 
Berry et al. PM 248 15 Decreased NR NR 
Berry et al. WG 44 28 Normal Normal NR 
Berry et al. KG 159 30 Normal Normal NR 
Strutchfield et al. LA 41 31 Normal NR 76 
Strutchfield et al. NH 40 24 Normal NR 77 
Sherwood et al. Father NR NR NR NR NR 
Sherwood et al. Son 96 NR Normal Normal 140 
Abderrahim et al. HI 142 20 Normal Normal NR 
Abderrahim et al. HA 230 NR Normal Normal NR 
Bakkaloglu et al. SG 53 22 Normal Normal Demised 
Bakkaloglu et al. AG 265 25 Normal Normal NR 
Bakkaloglu et al. BG 53 25 Normal Normal NR 
Bakkaloglu et al. IG 53 24 Normal Normal NR 
Bakkaloglu et al. MY 796 26 Decreased Decreased NR 
Bakkaloglu et al. FY 177 24 Decreased Decreased NR 
Bogdanovic et al. SC 35 13 Decreased Decreased 147 
Bogdanovic et al. MC 62 23 Normal Normal 145 
Motoyama et al. Case 1 62 45 Decreased Normal NR 
Motoyama et al. Case 2 62 29 Decreased Decreased NR 
Redahan et al. 1A NR NR NR NR NR 
Redahan et al. 1B NR NR NR NR NR 
Redahan et al. 2A NR NR Decreased Decreased NR 
Redahan et al. 2B NR NR NR NR NR 
This Report 304 238 16 Normal Normal 27 
This Report 405 97 34 Normal Normal 71 
This Report 404 71 14 Normal Normal 128 
This Report 413* 39 26 Normal Normal 182 
Neary et al. 213 NR 21 Decreased Normal NR 
Neary et al. 105 133 33 Normal Normal NR 
Neary et al. 212 NR 26 Normal Normal NR 
Neary et al. 214 NR 28 Normal Normal NR 
Neary et al. 103 NR 30 Normal Normal NR 
Neary et al. 223 NR 40 Normal Normal NR 
Mean  134 21    
Median  66 21    
Mode  53,04 Not Calculated    
Standard Deviation  159,92 7,48    
Table depicting the laboratory data of all the family members 
NR: Not recorded; * Index patient 
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Table 7: Biopsy Results 
Author Reference 
Patient 
Designation 
Previous 
classification 
IFM IgG IFM IgM IFM C3 
New 
Classification 
Berry et al. JM 3 Yes low Yes Yes CM 
Berry et al. PM 1 Yes low Yes Yes CM 
Berry et al. WG 1 Yes Yes Yes IM 
Berry et al. KG 1 Yes Yes Yes IM 
Strutchfield et al. LA 1 Yes Yes Yes IM 
Strutchfield et al. NH 1 Not done Not done Not done IM 
Sherwood et al. Father 1 Not done Not done Not done ? 
Sherwood et al. Son 1 No No No ? 
Abderrahim et al. HI 1 Not done Not done Not done ? 
Abderrahim et al. HA 1 Not done Not done Not done ? 
Bakkaloglu et al. SG 1 NR NR NR CM 
Bakkaloglu et al. AG 1 NR NR NR CM 
Bakkaloglu et al. BG 1 NR Yes Yes CM 
Bakkaloglu et al. IG 1 NR Yes Yes CM 
Bakkaloglu et al. MY 1 NR NR Yes CM 
Bakkaloglu et al. FY 1 NR NR Yes CM 
Bogdanovic et al. SC 1 Yes Yes Yes IM 
Bogdanovic et al. MC 3 Yes Yes Yes IM 
Motoyama et al. Case 1 1 No No Yes CM 
Motoyama et al. Case 2 1 No No Yes CM 
Redahan et al. 1A 1 Yes Yes No IM 
Redahan et al. 1B NS Yes Yes No IM 
Redahan et al. 2A 1 Yes Yes Yes IM 
Redahan et al. 2B 1 Yes Yes Yes IM 
This Report 304 1 Not done Not done Not done IM on LM 
This Report 405 1 Yes Yes Yes IM 
This Report 404 1 No No No ATN 
This Report 413* 1 Yes No Yes IM 
Neary et al. 213 3 No No Yes CM 
Neary et al. 105 3 No No Yes CM 
Neary et al. 212 3 No No Yes CM 
Neary et al. 214 3 No No Yes CM 
Neary et al. 103 3 NR NR NR CM 
Neary et al. 223 3 No No Yes CM 
Table containing the biopsy results of affected family members 
IFM: Immunofluorescence microscopy; CM: Complement mediated; IM: Immune complex Mediated; 
ATN: Acute tubular necrosis; ? Not enough information supplied for classification. * Index patient 
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Fourteen family members were included in the IM group from five reports. The mean and 
median age of diagnosis, of the family members in the IM group was 15 years. The mean 
follow up was six years. Most of the patients presented with proteinuria but quite a few 
studies did not go into detail regarding the clinical presentation. One report (Redahan et 
al.) did not include any information regarding the laboratory data. (16)  The other patients, 
however, had a mean serum creatinine of 83umol/L and a mean serum albumin of 24g/L. 
The mean age of ESRD was twenty years. Due to the small numbers, very little data is 
available to carry out a statistical analysis. The South African family is the largest family 
of affected family members in the immune-complex mediated group. 
 
Table 8: Immune complex mediated MPGN demographics 
Author 
Reference 
Patient 
Designation 
Gender 
Age at 
Diagnosis 
(years) 
Follow up 
(years) 
Previous 
MPGN 
New 
Classification 
Berry et al. WG Male 5 4 1 IM 
Berry et al. KG Male 7 5 1 IM 
Strutchfield et 
al. 
LA Male 1 2 1 IM 
Strutchfield et 
al. 
NH Male 1 5 1 IM 
Bogdanovic et 
al. 
SC Male 5 5 1 IM 
Bogdanovic et 
al. 
MC Female 5 3 3 IM 
Redahan et al. 1A Female 16 22 1 IM 
Redahan et al. 1B Male 18 13 NS IM 
Redahan et al. 2A Male 22 2 1 IM 
Redahan et al. 2B Male 15 2 1 IM 
This Report 304 Male 29 1 1 IM 
This Report 405 Male 15 8 1 IM 
This Report 404 Male 18 5 ATN ATN 
This Report 413* Female 13 8 1 IM 
Mean   15 6   
Median   15 5   
Mode   5 2   
Standard 
Deviation 
  
7,29 
 
5,78 
 
  
Table containing the demographics for the family members with immune complex mediated MPGN 
NS: Not specified; ATN: Acute Tubular Necrosis; IM: immune complex mediated; * Index patient 
 50 
 
 
Table 9: Immune mediated clinical presentation and residual findings 
Author 
Reference 
Patient 
Designation 
Hypertension 
Persistant 
HTN 
Haematuria 
Persistant 
Haematuria 
Proteinuria 
Persistant 
Proteinuria 
Berry et al. WG Yes Yes No No Yes NR 
Berry et al. KG Yes Yes No No Yes NR 
Strutchfield et 
al. 
LA No Yes No NR Yes Yes 
Strutchfield et 
al. 
NH No Yes Yes NR Yes Yes 
Bogdanovic et 
al. 
SC Yes No Yes No Yes Yes 
Bogdanovic et 
al. 
MC No Yes Yes Yes Yes Yes 
Redahan et al. 1A NR NR NR NR NR NR 
Redahan et al. 1B NR NR NR NR NR NR 
Redahan et al. 2A Yes NR Yes NR Yes NR 
Redahan et al. 2B NR NR NR NR NR NR 
This Report 304 Yes Yes Yes Yes Yes Yes 
This Report 405 No Yes Yes Yes Yes Yes 
This Report 404 No No Yes Yes Yes Yes 
This Report 413* Yes Yes Yes Yes Yes Yes 
Table containing the clinical presentation and residual clinical features on the family members affected by 
immune complex mediated MPGN; * Index patient 
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Table 10: Immune mediated laboratory data 
Author 
Reference 
Patient 
Designation 
Serum 
Creatinine 
umol/l 
Serum 
Albumin g/l 
Serum C3 Serum C4 
Berry et al. WG 44 28 Normal Normal 
Berry et al. KG 159 30 Normal Normal 
Strutchfield 
et al. 
LA 41 31 Normal NR 
Strutchfield 
et al. 
NH 40 24 Normal NR 
Bogdanovic 
et al. 
SC 35 13 Decreased Decreased 
Bogdanovic 
et al. 
MC 61 23 Normal Normal 
Redahan et 
al. 
1A NR NR NR NR 
Redahan et 
al. 
1B NR NR NR NR 
Redahan et 
al. 
2A NR NR Decreased Decreased 
Redahan et 
al. 
2B NR NR NR NR 
This Report 304 238 16 Normal Normal 
This Report 405 97 34 Normal Normal 
This Report 404 71 14 Normal Normal 
This Report 413* 39 26 Normal Normal 
Mean  83 24   
Median  53 25   
Mode  
Not 
Calculated 
Not 
Calculated 
  
Standard 
Deviation 
 66,61 7,39   
Table containing the laboratory data on the family members affected by immune 
complex mediated MPGN; * Index patient 
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Table 11: ESRD and Inheritance Pattern 
Author 
Reference 
Patient 
Designation 
Age at ESRD (years) Inheritance Pattern 
Berry et al. WG Not by follow up Multigenic/ X-linked 
Berry et al. KG Not by follow up Multigenic/ X-linked 
Strutchfield et 
al. 
LA Not by follow up X-linked Recessive 
Strutchfield et 
al. 
NH 5 Demised X-linked Recessive 
Bogdanovic et 
al. 
SC Not by Follow Up Multigenic 
Bogdanovic et 
al. 
MC 8.5 Multigenic 
Redahan et al. 1A 21 Autosomal Recessive 
Redahan et al. 1B 21 Autosomal Recessive 
Redahan et al. 2A 23 
Autosomal Recessive/ X-
linked 
Redahan et al. 2B 17 
Autosomal Recessive/ X-
linked 
This Report 304 
Demised before ESRD 
occurred 
Multigenic 
This Report 405 19 Multigenic 
This Report 404 Not by follow up Multigenic 
This Report 413* Not by follow up Multigenic 
Mean  20  
Median  21  
Mode  21  
Standard 
Deviation 
 2,28  
Table containing the age at which end stage renal disease (ESRD) occurred in family 
members affected by immune complex mediated MPGN and the family inheritance 
patterns suggested by studies; * Index patient 
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The complement- mediated families consisted of sixteen family members, had a mean age 
at diagnosis of fifteen years with a mean follow up period of six years (table 12). Almost 
half of the family members in this group had a previous diagnosis of MPGN type III 
compared to only one family member in the immune complex mediated group.  
 
Most of the family members presented with hypertension and proteinuria (table 13) and 
more family members had a decreased serum complement, 41% versus 14% in the immune 
mediated group (table 14). There are marked variations in the serum creatinine results, due 
to some family members presenting late or some had been previously diagnosed at other 
hospitals and their results at diagnosis were not available, hence the large standard 
deviation for the serum creatinine.  
 
Only three patients had ESRD by the time the reports were written and their ages 
fluctuated from 10 to 54 years, with a mean disease duration of twelve years. With regards 
to the inheritance pattern, there again is a marked variance but autosomal dominance 
occurs more frequently, however that is mainly due to the study by Neary et al. which had 
six family members (table 15) of the total sixteen family members. 
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Table 12: Complement mediated demographics 
Author 
Reference 
Patient 
Designation 
Gender 
Age at 
Diagnosis 
(years) 
Follow up 
(years) 
Previous 
MPGN 
New 
Classification 
Berry et al. JM Male 10 5 3 CM 
Berry et al. PM Female 9 2 1 CM 
Bakkaloglu et 
al. 
SG Male 3 1 1 CM 
Bakkaloglu et 
al. 
AG Male 10 7 1 CM 
Bakkaloglu et 
al. 
BG Male 3 6 1 CM 
Bakkaloglu et 
al. 
IG Male 10 1 1 CM 
Bakkaloglu et 
al. 
MY Male 9 4 1 CM 
Bakkaloglu et 
al. 
FY Male 13 2 1 CM 
Motoyama et 
al. 
Case 1 Female 14 1 1 CM 
Motoyama et 
al. 
Case 2 Female 9 31 1 CM 
Neary et al. 213 Male 4 NR 3 CM 
Neary et al. 105 Male 51 NR 3 CM 
Neary et al. 212 Male 28 NR 3 CM 
Neary et al. 214 Female 21 NR 3 CM 
Neary et al. 103 Female 25 NR 3 CM 
Neary et al. 223 Female 16 NR 3 CM 
Mean 
  
15 6 
  
Median 
  
10 3 
  
Mode 
  
10 2 
  
Standard 
Deviation 
  12,10 9,04   
Table containing the demographics for the family members with complement mediated MPGN 
CM: complement mediated MPGN; NR: Not recorded 
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Table 13: Complement mediated clinical presentation 
Author 
Reference 
Patient 
Designation 
Hypertension 
Residual 
Hypertension 
Haematuria 
Persistant 
Haematuria 
Proteinuria 
Persistant 
Proteinuria 
Berry et al. JM Yes NR Yes Yes Yes NR 
Berry et al. PM Yes NR Yes Yes Yes NR 
Bakkaloglu et 
al. 
SG Yes NR NR NR Yes NR 
Bakkaloglu et 
al. 
AG Yes NR NR NR Yes NR 
Bakkaloglu et 
al. 
BG No Yes NR NR Yes No 
Bakkaloglu et 
al. 
IG No Yes NR NR Yes No 
Bakkaloglu et 
al. 
MY Yes Yes NR NR Yes Yes 
Bakkaloglu et 
al. 
FY Yes No NR NR Yes No 
Motoyama et al. Case 1 No No Yes Yes Yes No 
Motoyama et al. Case 2 Yes No Yes No Yes Yes 
Neary et al. 213 Yes NR No NR Yes Yes 
Neary et al. 105 Yes NR Yes NR Yes Yes 
Neary et al. 212 Yes NR Yes NR Yes NR 
Neary et al. 214 No NR Yes NR Yes NR 
Neary et al. 103 Yes NR NR NR Yes NR 
Neary et al. 223 Yes NR Yes NR Yes NR 
Table containing the clinical presentation and residual clinical features on the family members affected by 
complement mediated MPGN 
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Table 14: Complement mediated laboratory data 
Author Reference 
Patient 
Designation 
Serum 
Creatinine 
umol/l 
Serum 
Albumin g/l 
Serum C3 Serum C4 
Berry et al. JM 26 18 Decreased NR 
Berry et al. PM 247 15 Decreased NR 
Bakkaloglu et al. SG 22 Normal Normal Demised 
Bakkaloglu et al. AG 25 Normal Normal CRF 
Bakkaloglu et al. BG 25 Normal Normal NR 
Bakkaloglu et al. IG 24 Normal Normal NR 
Bakkaloglu et al. MY 795 26 Decreased Decreased 
Bakkaloglu et al. FY 176 24 Decreased Decreased 
Motoyama et al. Case 1 62 45 Decreased Normal 
Motoyama et al. Case 2 62 29 Decreased Decreased 
Neary et al. 213 NR 21 Decreased Normal 
Neary et al. 105 133 33 Normal Normal 
Neary et al. 212 NR 26 Normal Normal 
Neary et al. 214 NR 28 Normal Normal 
Neary et al. 103 NR 30 Normal Normal 
Neary et al. 223 NR 40 Normal Normal 
Mean 
 
175 27 
  
Median 
 
62 26 
  
Mode 
 
53 26 
  
Standard Deviation  221,78 7,56   
Table containing the laboratory data on the family members affected by complement 
mediated MPGN. NR: Not Recorded 
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Table 15: Complement mediated age of ESRD and inheritance patterns 
Author 
Reference 
Patient 
Designation 
Age at ESRD Inheritance Pattern 
Berry et al. JM 
Not by follow 
up 
Multigenic 
Berry et al. PM 
Not by follow 
up 
Multigenic 
Bakkaloglu 
et al. 
SG NR 
Autosomal Dominant/ X-linked with incomplete 
penetrance 
Bakkaloglu 
et al. 
AG 10 
Autosomal Dominant/ X-linked with incomplete 
penetrance 
Bakkaloglu 
et al. 
BG NR 
Autosomal Dominant/ X-linked with incomplete 
penetrance 
Bakkaloglu 
et al. 
IG NR 
Autosomal Dominant/ X-linked with incomplete 
penetrance 
Bakkaloglu 
et al. 
MY NR 
Autosomal Dominant/ X-linked with incomplete 
penetrance 
Bakkaloglu 
et al. 
FY NR 
Autosomal Dominant/ X-linked with incomplete 
penetrance 
Motoyama et 
al. 
Case 1 NR Unclear 
Motoyama et 
al. 
Case 2 NR Unclear 
Neary et al. 213 10 Autosomal Dominant 
Neary et al. 105 
Not by follow 
up 
Autosomal Dominant 
Neary et al. 212 
Not by follow 
up 
Autosomal Dominant 
Neary et al. 214 
Not by follow 
up 
Autosomal Dominant 
Neary et al. 103 54 Autosomal Dominant 
Neary et al. 223 
Not by follow 
up 
Autosomal Dominant 
Table containing the age at which end stage renal disease (ESRD) occurred in family members 
affected by complement mediated MPGN and the family inheritance patterns suggested by studies. 
NR: Not Recorded 
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DISCUSSION 
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Redahan et al suggested that complement dysregulation played an important “role in the 
pathogenesis of immune complex mediated MPGN” as evidenced by the following (16) : 
 Familial cases of type II MPGN have been found to have mutations in complement 
factors and in complement factor proteins resulting in dysregulation of the 
complement cascade resulting in disease.  (16)  
 The study by Neary et al found a link between chromosome 1q, a locus containing 
multiple genes for factors affecting the complement cascade. (4)  
  A previous cohort of MPGN type I patients with both immunoglobulins and 
complement staining on IFM were found to have mutations in complement factor 
H (10, 4%) and complement factor I (6, 2%), suggesting dysregulation of the 
alternative pathway of the complement cascade. (19)  
 
This however does not explain why certain family members are affected, particularly in 
families with consanguineous marriages. Nor does it account for the other 83, 6% of 
people with MPGN type I. The study by Servais et al. also did not look into the underlying 
cause of MPGN  (19) was it caused by autoimmune diseases and of those diseases, which 
ones are affected by abnormal alternative pathway of complement? Thus, do those results 
apply to familial MPGN? While the above is useful in giving possible genes to look at in 
the future, more work needs to be done in this field.  
 
By doing the systematic review, it is clear that there are two forms of familial MPGN, 
namely the complement mediated and the immune complex mediated MPGN. Therefore, 
the current classification of MPGN needs to change and a fourth category added to the 
immune complex mediated group, that of familial or inherited immune complex-mediated 
MPGN, as the current classification only includes familial MPGN in the complement 
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mediated group. By splitting the two groups up into their pathogenesis, hopefully more 
information will be obtained in the future as to the underlying cause, particularly for the 
immune complex-mediated MPGN. 
 
The limitations of the Systematic review were:  
 Some studies did not contain all the information pertaining to their patients 
especially information regarding the biopsy specimens. 
 As well, some patients were diagnosed at other hospitals and their original results 
were not available. 
 The late presentation of some patients due to lack of funding. 
 Small cohort of patients. 
 
Despite the small cohort of patients, important data has been obtained particularly for 
future patients diagnosed with familial MPGN and their family members, as it provides 
evidence to promote the active work up of all family members under the age of 20 years, 
as the disease is rapidly progressive. Furthermore patients diagnosed with idiopathic 
immune complex mediated MPGN marked efforts should be directed to identify possible 
affected family members. 
 
Furthermore, this is the first study to assess a family in South Africa affected with familial 
MPGN of the immune-mediated type. It is also the largest cohort of family members 
affected by immune-mediated MPGN. By further studying this family, particularly with 
regards to an underlying genetic basis of their disease, more information will be gained to 
assist other families affected. 
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CONCLUSIONS 
 
Through the study and case report of this South African family with multiple members 
affected by familial MPGN as well as the systematic review of available studies of families 
affected by familial MPGN the following conclusions can be drawn: 
 
1. The underlying inheritance pattern for the South African family is possibly 
multigenic or autosomal recessive with incomplete penetrance. 
2. The current classification of immune complex-mediated MPGN needs to be 
modified to include an inherited form. 
3. A follow up study is required on the South African family to assess the possible 
underlying genetic basis of their disease. 
4. Lastly, an international collaboration is required to further study this disease due to 
the limited number of families affected worldwide. 
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